Document Detail

Recombinant bispecific single chain antibody fragments induce Fc gamma-receptor-mediated elimination of CD30+ lymphoma cells.
MedLine Citation:
PMID:  19345477     Owner:  NLM     Status:  MEDLINE    
Bispecific molecules (BSMs) facilitate the targeting of immune effector cells to tumor cells. Here we describe the construction and characterization of a recombinant BSM comprising two single chain fragments: H22(scFv), targeting the Fc gamma-receptor (CD64) on monocytes, and Ki4(scFv), targeting CD30 on Hodgkin lymphoma cells. A homologous, chemically-linked BSM has been described previously, but is heterogeneous and difficult to prepare. The recombinant version is easier to prepare and homogeneous, yet retains the antigen specificities and efficiently triggers CD64-related effector functions. The elimination of lymphoma cells was preferentially achieved by phagocytosis, not through the ADCC pathway additionally activated by the chemically-linked molecule.
Katharina Ranft; Theo Thepen; Rainer Fischer; Stefan Barth; Michael Stöcker
Related Documents :
20029417 - Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytoto...
19913427 - Distinct roles for the actin nucleators arp2/3 and hdia1 during nk-mediated cytotoxicity.
2859527 - Hybrid antibodies can target sites for attack by t cells.
2123477 - Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced b...
16641167 - Aromatase expression in endometriotic tissues and cell cultures of patients with endome...
21191687 - Human adipose-derived stem cells: potential clinical applications in surgery.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-04-03
Journal Detail:
Title:  Cancer letters     Volume:  282     ISSN:  1872-7980     ISO Abbreviation:  Cancer Lett.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-07-14     Completed Date:  2009-07-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600053     Medline TA:  Cancer Lett     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  187-94     Citation Subset:  IM    
Fraunhofer IME, Department of Pharmaceutical Product Development, Forckenbeckstr. 6, 52074 Aachen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Bispecific / therapeutic use*
Antibody-Dependent Cell Cytotoxicity
Antigens, CD30 / analysis,  immunology*
Cell Line
Cloning, Molecular
Hodgkin Disease / immunology,  therapy*
Immunoglobulin Fragments / therapeutic use*
Receptors, IgG / immunology*
Recombinant Proteins / therapeutic use
Reg. No./Substance:
0/Antibodies, Bispecific; 0/Antigens, CD30; 0/Immunoglobulin Fragments; 0/Receptors, IgG; 0/Recombinant Proteins; 0/immunoglobulin Fv

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress.
Next Document:  Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) ...